CIP
ROIV icon

Chartwell Investment Partners’s Roivant Sciences ROIV Stock Holding History

Chartwell Investment Partners’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-102,783
Closed -$1.2M – 439
2023
Q3 		$1.2M Hold
102,783
– – 0.05% 333
2023
Q2 		$1.04M Buy
102,783
+54,997
+115% +$492K 0.04% 351
2023
Q1 		$353K Buy
+47,786
New +$393K 0.01% 396

Other funds holding ROIV

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Chartwell Investment Partners's ROIV Position: Q4 2023 in Review

Chartwell Investment Partners sold out of Roivant Sciences (ROIV) in Q4 2023, closing a stake of 102,783 shares — an estimated $1.2M sold.

Chartwell Investment Partners first reported a position in ROIV in Q1 2023 and held it in 3 quarters. The position peaked at $1.2M in Q3 2023. 224 funds tracked by Wall St. Rank hold ROIV as of Q4 2023.

  • Chartwell Investment Partners reported no remaining Roivant Sciences position as of Q4 2023 after selling out during the quarter.
  • Chartwell Investment Partners sold 102,783 Roivant Sciences shares in Q4 2023, an estimated $1.2M.
  • Chartwell Investment Partners first reported a position in Roivant Sciences in Q1 2023 and held it in 3 quarters.
  • Chartwell Investment Partners's Roivant Sciences position peaked at $1.2M in Q3 2023.
  • 224 funds tracked by Wall St. Rank held Roivant Sciences as of Q4 2023.

Based on Chartwell Investment Partners's 13F filing for Q4 2023, filed 15 Feb 2024.